Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
Issued by National Institutes of Health · via Grants.gov — US federal funding opportunities
- Published
- 31 Aug 2026
- Closes
- 16 Jun 2028, 23:59 UTC
- Reference
- PAR-27-053
- Location
- United States
- Sector
- Healthcare & Pharma
Details
This notice of funding opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. For projects not requiring a phased research approach, applicants are encouraged to apply under a different funding activity code (e.g., PA-25-305 "Research Project Grant (Parent R01 Clinical Trial Required)" or its subsequent reissue). Eligibility: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.
CFDA number(s): 93.279
Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.
Context for bidders
We hold 411 notices from National Institutes of Health, going back to May 2023 — 383 of them still open. They buy mostly in Healthcare & Pharma, Education & Training and Water & Environment. There are 380 open Healthcare & Pharma tenders in United States. This one closes in 628 days.
More from this buyer
- Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)· closes 5 Nov
- Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)· closes 25 May
- NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)· closes 16 Nov
- Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional)· closes 10 Nov
- Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed)· closes 9 Oct
Similar Healthcare & Pharma tenders
- X-Ray Equipment Set — 1 kits, NSN 6545016906022· closes 5 Oct
- Development of monoclonal antibodies to prevent and treat infections from Flaviviruses· closes 13 Apr
- Development of cell-free protein synthesis platforms for discovery and/or production of biologicals· closes 13 Apr
- Advancing bio-printing of living cells for regenerative medicine· closes 22 Sept
- Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential· closes 13 Apr
Before you bid on this tender
A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.
- Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
- Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
- Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
- Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
- Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
- Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.
More Healthcare & Pharma tenders
- Open House: Partners Jeugdhulp segment 2, 3 en 4 Noord-LimburgModulaire Gemeenschappelijke Regeling Sociaal Domein Limburg-Noord · Netherlands
- DAS ICT TabletsStichting Protestants Christelijk Primair Onderwijs Groene Hart · Netherlands
- DAS TabletsQuadraten · Netherlands
- Hoogspecialistische Jeugdhulp ('HSJ')Regionale Inkooporganisatie Groninger Gemeenten (RIGG) · Netherlands
- Apeldoorn Werkt MeeGemeente Apeldoorn, team Inkoop · Netherlands
FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.
Verify & apply on the official portal →